Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Analysis of a Training Intervention for Pulmonary Embolism Diagnosis in Emergency Department (APEED)

Condition:   Pulmonary Embolism
Intervention:   Behavioral: Training Intervention for PE Diagnosis
Sponsor:   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Recruiting - verified January 2017

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Conditions:   Prostate Cancer;   Venous Thromboembolism;   Lymphocele After Surgical Procedure;   Deep Venous Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Subcutaneous Heparin
Sponsor:   Johns Hopkins University
Not yet recruiting - verified January 2017

Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty

Conditions:   DVT - Deep Vein Thrombosis;   PE - Pulmonary Thromboembolism
Interventions:   Drug: Aspirin;   Device: (Post- discharge) Mechanical Compression Device
Sponsors:   Washington University School of Medicine;   Medical Compression Systems
Not yet recruiting - verified January 2017

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

Condition:   Left Ventricular Thrombosis
Interventions:   Drug: Apixaban 5 MG Oral Tablet [ELIQUIS];   Drug: Warfarin Sodium
Sponsors:   University of Science Malaysia;   INSTITUT JANTUNG NEGARA
Recruiting - verified January 2017

Randomized Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Conditions:   Pulmonary Embolism;   Thrombotic Disease
Interventions:   Drug: DS-1040b;   Drug: placebo
Sponsors:   Daiichi Sankyo Inc.;   International Trial Expertise and Advisory Servies (ITREAS);   Medpace, Inc.
Recruiting - verified January 2017

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2017

Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm

Conditions:   Atrial Fibrillation;   Venous Thromboembolism;   Pulmonary Embolism
Interventions:   Other: XAPPORT;   Other: Expert Panel ("gold standard")
Sponsors:   Bayer;   Janssen Research & Development, LLC
Not yet recruiting - verified January 2017

Registry Of Acute meDical Emergencies in Brazil

Conditions:   Acute Coronary Syndromes;   Heart Failure;   Pulmonary Edema;   Aortic Aneurysm, Familial Thoracic 1;   Chest Pain;   Pulmonary Embolism;   Syncope
Intervention:   Other: no intervention
Sponsor:   University of Sao Paulo General Hospital
Recruiting - verified January 2017

Tumor-educated Platelets in Venous Thromboembolism

Conditions:   Neoplasms;   Venous Thromboembolism
Intervention:  
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified January 2017

INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis

Condition:   Superficial Vein Thrombosis
Interventions:   Drug: any drug;   Procedure: any procedure/surgery;   Other: Any non-pharmacological treatment of SVT
Sponsor:   GWT-TUD GmbH
Recruiting - verified January 2017

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban;   Drug: Standard-of-care
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Active, not recruiting - verified January 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism

Condition:   Pulmonary Embolism
Intervention:  
Sponsors:   McMaster University;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study

Condition:   Venous Thromboembolism
Interventions:   Drug: Enoxaparin;   Drug: Placebo
Sponsor:   University Hospital, Brest
Recruiting - verified January 2017

Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE

Conditions:   Elderly;   Pulmonary Embolism;   Anticoagulants
Intervention:   Other: 4 blood samples
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Ministry of Health, France
Recruiting - verified September 2016

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified January 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified January 2017

Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism

Conditions:   Cancer;   Deep Venous Thrombosis;   Pulmonary Embolism
Intervention:  
Sponsors:   Harry R. Buller;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   University Medical Center Groningen;   Slotervaart Hospital;   Hôpital Louis Mourier;   Università degli Studi 'G. d'Annunzio' Chieti e Pescara;   Instituto Nacional de Cancerologia de Mexico
Completed - verified January 2017

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Conditions:   Chronic Obstructive Pulmonary Disease;   Patients Hospitalized for a COPD Exacerbation
Intervention:   Other: PEP
Sponsor:   University Hospital, Brest
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication

Condition:   Venous Thrombosis
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Rosuvastatin
Sponsors:   Leiden University Medical Center;   Netherlands Heart Foundation
Completed - verified January 2017

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Unfractionated heparin;   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Condition:   Deep Vein Thrombosis
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Unfractionated heparin;   Drug: Warfarin
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale

Conditions:   Recent Stroke;   Pulmonary Embolism;   Patent Foramen Ovale
Intervention:  
Sponsor:   University Hospital, Brest
Completed - verified January 2017

Dose-confirmatory Bridging Study in Total Knee Replacement

Condition:   Venous Thromboembolism
Interventions:   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Dose-confirmatory Bridging Study in Total Hip Replacement

Condition:   Venous Thromboembolism
Interventions:   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

Condition:   HIV
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 29, 2016

Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.

Condition:   Pulmonary Embolism
Interventions:   Drug: warfarin;   Drug: placebo of warfarin
Sponsor:   University Hospital, Brest
Completed - verified January 2017

Development of Computer-aided Detection and Diagnosis From Imaging Techniques

Condition:   Cancer
Intervention:  
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified March 17, 2016